Catalyst overview
Research summary
This catalyst tracks a Phase 1b data readout for Botensilimab (AGEN1181) + balstilimab in Cancer, Sarcoma. The expected timing is based on the latest available company guidance and may change.
4/28/25- Presented initial results from pan-cancer NEOASIS study at AACR. 11/10/25:- Reported pan-tumor data. 02/10/26:- Translational and biomarker analyses poster on BOT+BAL in cold refractory tumors at AACR-IO February 19, 2026. 03/16/26:- France AAC expanded Jan 2026 to include soft-tissue sarcoma for BOT+BAL. 05/11/26:- France AAC soft-tissue sarcoma access ongoing; BAP Pharma now global partner; named-patient access expanded. 07/17/26:- Spanish expanded-access sarcoma real-world data poster at ESMO on October 26, 2026. 08/06/26:- PR No update.
Verification
Confirm timing and program details against the company announcement or filing.